Opterion successfully secures EUR 8.4m Bridge Financing Round

Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!

Introducing you to our Contract Research Organization

The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!

A Retrospective Look To 2020

This year has been unlike any other, but at HEMEX we have continued with a positive spirit through it all. In this article, we want to take a look back at 2020 as we look ahead to all that we can accomplish next year.
2020 has turned our lives upside down. It started as an exciting yea

Sleepiz is one of the winners of the 23rd annual IMD Startup Competition

In times of high uncertainty like this 2020 year, it is necessary to celebrate and savor the victories. We want to congratulate our portfolio company Sleepiz for its well-deserved success in winning collaboration with one of the three Executive MBA cohorts at the beginning of 2021

ASPIVIX Reports Positive First-In-Women Results Using Novel Suction-Based Cervical Device in IUD Procedures

Our portfolio company ASPIVIX SA announced last week the completion of and interim analysis results from its Phase I first-in-women trial. The two-phase ADVANCE Women trial is assessing the usability, efficacy, and safety of the investigational CAREVIX, the innovative device designed as a modern and gentler alternative. Warmest congratulations on your achievement, ASPIVIX!